Search
Serine/threonine-protein kinase Nek4
go.drugbank.com/bio_entities/BE0009498TargetHumansRequired for normal cell cycle arrest in response to double-stranded DNA damage
Synonyms: Never in mitosis A-related kinase 4Lumateperone
go.drugbank.com/drugs/DB06077ApprovedInvestigational[A189093] Further, not only is the new antipsychotic selective for dopamine (D2) receptors in the mesolimbic and mesocortical brain regions, but it also has minimal off-target activity. … [A189093] It has a unique receptor binding profile and differs from other antipsychotics in that it modulates glutamate, serotonin and dopamine, which are all neurotransmitters that contribute to the pathophysiology
Categories: Dopamine D2 Receptor Agonists, Cytochrome P-450 SubstratesPlantago seed
go.drugbank.com/drugs/DB11097ApprovedInvestigationalPlatango seeds refer to the seeds collected from various species of plantago trees. It is found in some laxatives for treating occasional constipation and restoring regularity in bowel movements. … Regardless, this agent is most predominantly used as a gentle laxative agent in many parts of the world that is more commonly referred as psyllium or psyllium husk.
Mixtures: Multilax 1 CapProducts: DG health Sugar Free, Ri MucilTislelizumab
go.drugbank.com/drugs/DB14922ApprovedInvestigational[L49439] Tislelizumab was also approved by the FDA on March 14, 2024.[L50346] It has subsequently been approved for additional cancers in the US and EU. [L49349] … This approval was based on positive results demonstrated in the RATIONALE 302 study, where an 8.6-month median overall survival rate was observed for tislelizumab treatment compared to 6.3-month for chemotherapy
Categories: PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors, PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitorsErdafitinib
go.drugbank.com/drugs/DB12147ApprovedInvestigational[L5956, L5959] Considering urothelial cancer is statistically the fourth most common kind of cancer in the world, the introduction of erdafitinib offers a much-needed new option in the ever-expanding therapeutic … In early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for
Categories: Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic IndexProducts: BALVERSA 3 MG FİLM KAPLI TABLET, 56 ADET, BALVERSA 3 MG FİLM KAPLI TABLET, 84 ADETSARS-CoV-2 virus recombinant spike (S) protein receptor binding domain (RBD) fusion heterodimer (B.1.351-B.1.1.7 strains)
go.drugbank.com/drugs/DB18705Approved[L48902,L48907] Bimervax was issued marketing authorization in the EU in March 2023 for use as a booster dose in patients who have previously received an mRNA COVID-19 vaccine.[L48907] … [A262551] It is produced using recombinant DNA technology in CHO cell lines and is marketed by Hipra Human Health S.L. for the European market.
Synonyms: SARS-CoV-2 virus recombinant spike (S) protein receptor binding domain (RBD) fusion heterodimer – B.1.351-B.1.1.7 strains, SARS-CoV-2 virus recombinant spike (S) protein receptor binding domain (RBD) fusion heterodimer (B.1.351-B.1.1.7 strains)Ciltacabtagene autoleucel
go.drugbank.com/drugs/DB16738ApprovedInvestigational[A245854] While normally expressed on plasma blasts and plasma cells, BCMA is widely expressed on malignant plasma cells and most multiple myeloma cell lines, making it a choice target in the development … [A245854] Carvykti was first approved by the FDA in February 2022 for the treatment of relapsed or refractory multiple myeloma in treatment-experienced patients.[L40744]
Synonyms: Autologous bi-epitope BCMA-targeted CAR T-cellsDL-dimyristoylphosphatidylglycerol
go.drugbank.com/drugs/DB11284ApprovedDL-dimyristoylphosphatidylglycerol is a phospholipid used in commercially available pharmaceutical preparations to solubilize drugs for injection.
Synonyms: DL-dimyristoylphosphatidylglycerolIbalizumab
go.drugbank.com/drugs/DB12698ApprovedInvestigationalThis drug was approved in March 2018 for the management of treatment-resistant HIV [L1554]. … It is an advanced and current antibody in development for the treatment of HIV/AIDS. It has been developed by Taimed biologics and Theratechnologies [L1558, L1554].
Categories: HIV 1 Post-attachment Fusion Inhibitors, Human Immunodeficiency Virus 1 Post-attachment Fusion InhibitorAcetophenazine
go.drugbank.com/drugs/DB01063ApprovedIt is also used to help treat false perceptions (e.g. hallucinations or delusions). It primarily targets the dopamine D2 receptor. … Acetophenazine is an antipsychotic drug of moderate-potency. It is used in the treatment of disorganized and psychotic thinking.
Categories: Dopamine D2 Receptor Antagonists, Heterocyclic Compounds, 3-Ring